Why Si-Bone Stock Soared by Almost 20% on Tuesday
Key Points
It posted rather encouraging first-quarter results.
It also raised (albeit modestly) certain full-year guidance items.
- 10 stocks we like better than SI-Bone ›
On Tuesday, Si-Bone (NASDAQ: SIBN) stock was a standout not only in its medical devices niche, but within the broader healthcare sector. That's because its shares experienced a bull stampede after investors were impressed by the company's first-quarter results, which were published after market close on Monday.
A good start to the financial year
Si-Bone booked revenue of $52.6 million during the period, a figure that was up by more than 11% year over year. That tally didn't quite meet the average analyst estimate, which anticipated a figure of just under $52.9 million.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
The story was different on the medical device maker's bottom line. It significantly narrowed its net loss under generally accepted accounting principles (GAAP) to $4.3 million, or $0.10 per share, from the year-ago deficit of $6.5 million.
It was an eventful quarter for Si-Bone, as among other developments, it pushed into international markets with key products and received Food and Drug Administration (FDA) clearance for its 3D-printed titanium implant system iFuse INTRA Ti.
With the strong momentum it's shown from both its recent developments and existing business, the company feels it's well primed for the future. It quoted CEO Laura Francis as saying, "we are well positioned to accelerate revenue growth through 2026 and into 2027."
Cautious increases
Not for the first time in recent quarters, Si-Bone raised its full-year guidance. It now believes it will take in $230 million to $233 million across 2026, up a shade from its previous forecast of $228.5 million to $232.5 million. Its gross profit margin should be around 79%, one percentage point higher than the preceding estimate of 78%.
Si-Bone is one of those medical device makers that has found a lucrative niche within the vast healthcare industry and has established significant expertise in it. I buy Francis' sunny projection of the future, and I'd be a buyer of its stock.
Should you buy stock in SI-Bone right now?
Before you buy stock in SI-Bone, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and SI-Bone wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $460,826!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,345,285!*
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 12, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
